Keryx Does not Meet Primary Endpoint in Colorectal Cancer

Keryx Biopharmaceuticals, Inc. confirmed the fact that Phase 3 "X-PECT" clinical trial assessing perifosine in affected individuals with refractory sophisticated colorectal cancer didn't satisfy the first endpoint of improving overall existance versus capecitabine panacea.

This particularly Phase 3 trial was done pursuant to a Special Protocol Assessment (SPA) contract together with the FDA. 468 affected individuals at sixty-five U.S. sites took part within this study.

Ron Bentsur, Chief Executive Officer of Keryx, said, "Many of us are extremely dissatisfied together with the outcome of the study. We acknowledge the private investigators who took part in almost everything that believes have been a well-run study, despite the outcome. We shall evaluate even if our Phase 3 evaluation of Perifosine in relapsed/refractory numerous myeloma will not stop as planned."

Mr. Bentsur stated further, "With about $31 million in cash as of March 31, 2012, as well as a well-controlled burn rate, all of us plan to focus our assets at the pending finishing of the Zerenex (ferric citrate) a long time Phase 3 study for end stage renal disease (ESRD) affected individuals with hyperphosphatemia, anticipated in the 4th quarter of 2012, as well as the New Drug Application (NDA) filing for Zerenex which could hopefully follow abruptly further."